Key result
In children with dilated cardiomyopathy, having multiple high-risk adrenergic receptor genotypes was associated with a 2.57-fold increased risk of requiring mechanical circulatory support while awaiting transplantation, though beta-blocker therapy attenuated the decline in cardiac function.
Why the study?
Does β-blocker therapy improve cardiac function and hemodynamics in children with dilated cardiomyopathy and high-risk adrenergic receptor genotypes?
Population
135 children with dilated cardiomyopathy (91 with advanced DCM, 44 with stable DCM), mean age 8.5 years.
Comparison
β-blocker therapy in the context of high-risk… vs No β-blocker therapy
Design
Cohort
Follow-up
1 year
Authors
Loading...
May support genotype-informed risk stratification in pediatric dilated cardiomyopathy; leaves open whether early beta-blockers improve outcomes in high-risk genotypes.
Cohort (n=135)
Yes
Does β-blocker therapy improve cardiac function and hemodynamics in children with dilated cardiomyopathy and high-risk adrenergic receptor genotypes?
Hazard Ratio: 2.57 (95% CI 1.05–7.23)
p-value: p=0.05
High-risk adrenergic receptor genotypes may identify children with dilated cardiomyopathy who are at higher risk for decompensation and who may specifically benefit from early β-blocker therapy.
Reddy et al. (2014) conducted a cohort in Dilated cardiomyopathy (n=135). Multiple high-risk adrenergic receptor genotypes (≥2 ADR high-risk genotypes) vs. <2 ADR high-risk genotypes was evaluated on Requirement of mechanical circulatory support (VAD/ECMO) while awaiting transplantation (HR 2.57, 95% CI 1.05-7.23, p=0.05). In children with dilated cardiomyopathy, having multiple high-risk adrenergic receptor genotypes was associated with a 2.57-fold increased risk of requiring mechanical circulatory support while awaiting transplantation, though beta-blocker therapy attenuated the decline in cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: